Authorization

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN

NEW YORK, Oct. 17, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceuticals, Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers.A  The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-06719, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquiredA BioMarin securities between February 28, 2020 and August 18, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.If you are a shareholder who purchased BioMarin securities during the class period, you have until November 24, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.A  A copy of the Complaint can be obtained at www.pomerantzlaw.com.A A To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.comA or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.A  [Click here for information about joining the class action]A BioMarin is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.A  The Company's product candidates include, among others, valoctocogene roxaparvovec, an investigational adeno-associated virus ("AAV") gene therapy, which is in Phase 3 clinical development for the treatment of patients with severe hemophilia A.Based on BioMarin's Phase 1/2 study results, the investing and medical community viewed valoctocogene roxaparvovec as a likely candidate for becoming the first gene therapy approved by the U.S. Food and Drug Administration ("FDA") for hemophilia in the U.S.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2020    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
30